文献速递乳腺癌

长春氟宁联合卡培他滨对比卡培他滨单药治疗经蒽环类和紫杉类治疗的晚期乳腺癌的随机III期试验

Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
PubMed 文献 · Ann Oncol · 2018-01-01

这项随机III期试验纳入770例既往接受过蒽环类且对紫杉类耐药的局部复发/转移性乳腺癌患者,比较长春氟宁联合卡培他滨(VC)与卡培他滨单药的疗效和安全性。主要终点无进展生存期(PFS)在VC组显著延长(中位5.6 vs 4.3个月,HR 0.84,95%CI 0.71-0.99,P=0.043),但总生存期无显著差异(中位13.9 vs 11.7个月,HR 0.98,95%CI 0.83-1.15,P=0.77)。VC组中性粒细胞减少更常见,而卡培他滨单药组手足综合征更常见,两组生活质量无差异。

要点

  • VC方案较卡培他滨单药显著改善PFS(HR 0.84,P=0.043),但OS无差异。
  • VC组4级中性粒细胞减少发生率更高(12% vs 1%),发热性中性粒细胞减少2% vs 0.5%。
  • 卡培他滨单药组3级手足综合征更常见(19% vs 4%),周围神经病变两组均少见。

核心结论

  • 在蒽环类和紫杉类经治的局部复发/转移性乳腺癌患者中,长春氟宁联合卡培他滨较卡培他滨单药轻度改善PFS,安全性可接受。

研究设计与样本

  • 随机III期试验,纳入770例既往接受或对蒽环类耐药且对紫杉类耐药的局部复发/转移性乳腺癌患者。
  • 随机分配至长春氟宁(280 mg/m2,第1天)联合口服卡培他滨(825 mg/m2,每日两次,第1-14天)每3周方案,或卡培他滨单药(1250 mg/m2,每日两次,第1-14天)每3周方案。
  • 主要终点为独立评审委员会评估的PFS,研究有90%把握度检测PFS改善30%。

主要发现

  • VC组中位PFS为5.6个月,卡培他滨单药组为4.3个月(HR 0.84,95%CI 0.71-0.99;log-rank P=0.043)。
  • VC组中位OS为13.9个月,卡培他滨单药组为11.7个月(HR 0.98,95%CI 0.83-1.15;log-rank P=0.77)。
  • 两组生活质量无差异。
  • VC组最常见不良事件为血液学和胃肠道毒性;4级中性粒细胞减少发生率为12% vs 1%,发热性中性粒细胞减少为2% vs 0.5%。
  • 卡培他滨单药组3级手足综合征发生率更高(19% vs 4%);周围神经病变两组均少见(3级:1% vs 0.3%)。

临床怎么用

  • 对于蒽环类和紫杉类经治的晚期乳腺癌患者,长春氟宁联合卡培他滨可作为卡培他滨单药之外的一个治疗选择,但需权衡PFS轻度获益与血液学毒性增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Capecitabine is an approved standard therapy for anthracycline- and taxane-pretreated locally advanced or metastatic breast cancer (BC). Vinflunine has demonstrated single-agent activity in phase II studies in this setting and activity and tolerability when combined with capecitabine. We compared the combination of vinflunine plus capecitabine (VC) with single-agent capecitabine. PATIENTS AND METHODS: Patients with locally recurrent/metastatic BC previously treated or resistant to an anthracycline and resistant to taxane therapy were randomly assigned to either vinflunine (280 mg/m2, day 1) plus oral capecitabine [825 mg/m2 twice daily (b.i.d.), days 1-14] every 3 weeks (q3w) or single-agent oral capecitabine (1250 mg/m2 b.i.d., days 1-14) q3w. The primary end point was progression-free survival (PFS) assessed by an independent review committee. The study had 90% power to detect a 30% improvement in PFS. RESULTS: Overall, 770 patients were randomised. PFS was significantly longer with VC than with capecitabine alone [hazard ratio, 0.84, 95% confidence interval (CI), 0.71-0.99; log-rank P = 0.043; median 5.6 versus 4.3 months, respectively]. Median overall survival was 13.9 versus 11.7 months with VC versus capecitabine alone, respectively (hazard ratio, 0.98; 95% CI, 0.83-1.15; log-rank P = 0.77). No difference in quality of life was observed between the two treatment arms. The most common adverse events (NCI CTCAE version 3.0) in the combination arm were haematological and gastrointestinal. Grade 4 neutropenia was more frequent with VC (12% versus 1% with capecitabine alone); febrile neutropenia occurred in 2% versus 0.5%, respectively. Hand-foot syndrome was less frequent with VC (grade 3: 4% versus 19% for capecitabine alone). Peripheral neuropathy was uncommon in both arms (grade 3: 1% versus 0.3%). CONCLUSIONS: Vinflunine combined with capecitabine demonstrated a modest improvement in PFS and an acceptable safety profile compared with capecitabine alone in patients with anthracycline- and taxane-pretreated locally recurrent/metastatic BC. CLINICALTRIALS.GOV: NCT01095003.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Martin M, Campone M, Bondarenko I, et al. Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane. Ann Oncol. 2018. PMID: 29447329. doi:10.1093/annonc/mdy063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。